Saga Investments LLC
http://www.decode.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Saga Investments LLC
Novo Nordisk Not Unnerved By ‘Quarterly Blip’
Sales of Wegovy and Ozempic were strong again in the second quarter and while they were shy of analyst expectations, the Copenhagen-based giant is confident of continuing demand despite competition from Eli Lilly’s Zepbound.
ADA: Zepbound Could Take Sleep Apnea Patients Off CPAP
Lilly’s incretin looks set to add obstructive sleep apnea to its label – an indication in which Novo Nordisk has so far shown no interest.
Finance Watch: Clinical-Stage Autoimmune Start-Ups Garner Big Investments
Private Company Edition: Attovia will advance two anti-IL-31 programs with its $105m in series B funding, while ImmuNext secured $575m in a Royalty Pharma deal for its Sanofi-partnered drug. Also, Bluejay and Aardvark raised $182m and $85m, respectively, in series C rounds.
Verve Not Ready To Pull Plug On Anti-PCSK9 Gene Editing Candidate
The company told Scrip that the sixth patient with elevated liver enzymes and low platelets recovered after hospital observation and oral steroids, and it may still continue VERVE-101’s development.
Company Information
- Other Names / Subsidiaries
-
- deCODE genetics ehf
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice